Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Andrew M. Lowy

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7106-0735; OpenAlex author ID A5089839809; NIH RePORTER profile ID 1886399. Sources: ClinicalTrials.gov.

Their work

Papers
84 (first author 1, last author 14)
Trials
2 (principal investigator on 1)
Grants
11
Labs led
1
Collaborators
340
Papers, trials and grants by year

2011: 1 paper · 2012: 3 papers · 2013: 4 papers · 2014: 5 papers · 2015: 1 paper, 1 grant · 2016: 5 papers · 2017: 4 papers · 2018: none · 2019: 5 papers, 1 trial, 2 grants · 2020: 3 papers · 2021: 12 papers, 1 grant · 2022: 4 papers, 1 grant · 2023: 11 papers, 1 grant · 2024: 9 papers, 1 trial, 1 grant · 2025: 7 papers, 1 grant · 2026: 10 papers, 3 grants

Papers 50 of 84

  1. Corrigendum to "Histamine H1 receptor: a potential therapeutic target for pancreatic ductal adenocarcinoma". Co-author DOI 10.1016/j.jpet.2026.104305↗
  2. ZBTB11 depletion targets metabolic vulnerabilities in KRAS inhibitor-resistant PDAC. Co-author DOI 10.1038/s41589-025-01978-1↗
  3. Selective targeting of NRF2-high pancreatic ductal adenocarcinoma with an NQO1-activatable prodrug. Co-author DOI 10.1073/pnas.2511733123↗
  4. Targeting the αvβ5 Integrin Modifies the TGFβ-Rich Tumor Microenvironment of Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-4223↗
  5. The Times They Are A-Changin': Pancreatic Cancer Surgery in the RAS Inhibitor Era. First author DOI 10.1245/s10434-026-20525-3↗
  6. Histamine H1 receptor: A target to treat pancreatic ductal adenocarcinoma (PDAC) by repurposing approved H1-antihistamines? Co-author DOI 10.46439/signaling.4.094↗
  7. Pancreatic Adenocarcinoma, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. Co-author DOI 10.6004/jnccn.2026.0046↗
  8. CA19-9 promotes liver metastasis of pancreatic cancer through E-selectin mediated extravasation Co-author DOI 10.64898/2026.04.08.717301↗
  9. Metabolic Salvage and Acyl-chain Remodeling Support Glycosphingolipid Synthesis within the PDAC Tumor Microenvironment Co-author DOI 10.64898/2026.04.14.718544↗
  10. CA19-9 induces microenvironment remodeling in pancreatic ductal adenocarcinoma Co-author DOI 10.64898/2026.05.22.727290↗
  11. Macropinocytosis maintains CAF subtype identity under metabolic stress in pancreatic cancer. Co-author DOI 10.1016/j.ccell.2025.06.021↗
  12. Histamine H1 Receptor: A potential therapeutic target for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.jpet.2025.103573↗
  13. Spatial mapping of transcriptomic plasticity in metastatic pancreatic cancer. Co-author DOI 10.1038/s41586-025-08927-x↗
  14. Author Correction: Collagenolysis-dependent DDR1 signalling dictates pancreatic cancer outcome. Co-author DOI 10.1038/s41586-025-09285-4↗
  15. Self-amplifying NRF2-EZH2 epigenetic loop converts KRAS-initiated progenitors to invasive pancreatic cancer. Co-author DOI 10.1038/s43018-025-01003-3↗
  16. Leveraging autophagy and pyrimidine metabolism to target pancreatic cancer Co-author DOI 10.1101/2025.05.29.656904↗
  17. MICAL2 Promotes Pancreatic Cancer Growth and Metastasis. Last author DOI 10.1158/0008-5472.can-24-0744↗
  18. Body composition measurements and clinical outcomes in patients with resectable pancreatic adenocarcinoma - analysis from SWOG S1505. Co-author DOI 10.1016/j.gassur.2023.12.022↗
  19. Glutamine mimicry suppresses tumor progression through asparagine metabolism in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s43018-023-00649-1↗
  20. Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2024.01.013↗
  21. A Randomized Trial of Two Remote Health Care Delivery Models on the Uptake of Genetic Testing and Impact on Patient-Reported Psychological Outcomes in Families… Co-author DOI 10.1053/j.gastro.2024.01.042↗
  22. The oncofetal protein IMP1 regulates the transcriptomic landscape to drive early events in pancreatic cancer progression and growth Co-author DOI 10.1101/2024.06.28.601273↗
  23. Macropinocytosis controls metabolic stress-driven CAF subtype identity in pancreatic cancer Co-author DOI 10.1101/2024.11.29.625709↗
  24. Inhibition of SUMOylation Induces Adaptive Antitumor Immunity against Pancreatic Cancer through Multiple Effects on the Tumor Microenvironment. Co-author DOI 10.1158/1535-7163.mct-23-0572↗
  25. The effect of extracellular matrix on the precision medicine utility of pancreatic cancer patient-derived organoids. Co-author DOI 10.1172/jci.insight.172419↗
  26. The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals. Co-author DOI 10.6004/jnccn.2023.7097↗
  27. Single-cell mapping identifies MSI+ cells as a common origin for diverse subtypes of pancreatic cancer. Co-author DOI 10.1016/j.ccell.2023.09.008↗
  28. Pancreatic ductal adenocarcinoma induces neural injury that promotes a transcriptomic and functional repair signature by peripheral neuroglia. Last author DOI 10.1038/s41388-023-02775-7↗
  29. Smarcd3 is an epigenetic modulator of the metabolic landscape in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-023-35796-7↗
  30. A super-enhancer-regulated RNA-binding protein cascade drives pancreatic cancer. Co-author DOI 10.1038/s41467-023-40798-6↗
  31. Pancreatic cancer cells upregulate LPAR4 in response to isolation stress to promote an ECM-enriched niche and support tumour initiation. Co-author DOI 10.1038/s41556-022-01055-y↗
  32. Publisher Correction: Collagenolysis-dependent DDR1 signalling dictates pancreatic cancer outcome. Co-author DOI 10.1038/s41586-023-05920-0↗
  33. A pancreatic cancer mouse model with human immunity Co-author DOI 10.1101/2023.05.24.542127↗
  34. Tumor-resident regulatory T cells in pancreatic cancer express the αvβ5 integrin as a targetable activation marker Co-author DOI 10.1101/2023.05.24.542137↗
  35. Syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-22-3645↗
  36. Dual Inhibition of KRASG12D and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-23-1313↗
  37. Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance. Co-author DOI 10.1158/1940-6207.capr-22-0529↗
  38. Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detectio… Co-author DOI 10.1016/j.gie.2021.10.025↗
  39. Collagenolysis-dependent DDR1 signalling dictates pancreatic cancer outcome. Co-author DOI 10.1038/s41586-022-05169-z↗
  40. Fluorescent Anti-MUC5AC Brightly Targets Pancreatic Cancer in a Patient-derived Orthotopic Xenograft. Co-author DOI 10.21873/invivo.12676↗
  41. Establishment of Patient-Derived Pancreatic Cancer Organoids from Endoscopic Ultrasound-Guided Fine-Needle Aspiration Biopsies. Co-author DOI 10.5009/gnl210166↗
  42. Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2020.7328↗
  43. Phase I Trial of Stereotactic Body Radiation Therapy Dose Escalation in Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2021.02.008↗
  44. Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Co-author DOI 10.1038/s41586-021-04176-w↗
  45. Recommendations for a More Organized and Effective Approach to the Early Detection of Pancreatic Cancer From the PRECEDE (Pancreatic Cancer Early Detection) Co… Co-author DOI 10.1053/j.gastro.2021.08.036↗
  46. Neoadjuvant Checkpoint Blockade in Lynch Syndrome-Related Pancreatic Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000001742↗
  47. A MET Targeting Antibody-Drug Conjugate Overcomes Gemcitabine Resistance in Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-20-3210↗
  48. Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: … Co-author DOI 10.1158/1078-0432.ccr-21-1789↗
  49. Targeting the IGF-Axis Potentiates Immunotherapy for Pancreatic Ductal Adenocarcinoma Liver Metastases by Altering the Immunosuppressive Microenvironment. Co-author DOI 10.1158/1535-7163.mct-20-0144↗
  50. Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study. Co-author DOI 10.1158/1940-6207.capr-20-0642↗

Trials 2

  1. Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer Study chair NCT06639724↗
  2. Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer Principal investigator NCT03697564↗

Grants 11

  1. Targeted degradation of glycoimmune checkpoints Siglec-7 and -9 for cancer immunotherapy R01CA304089↗
  2. Defining the Role of MICAL2 in KRAS Mediated Pancreatic Duct Neoplasia R01CA309448↗
  3. Regulation of PDAC metabolism and immunity by collagen and its cleavage products U01CA274295↗
  4. Full Project 1: Defining Mechanisms of MICAL-dependent Pancreatic Cancer Cell Migration U54CA285115↗
  5. Clinical Accelerator Initiative grant: Andrew Lowy AWARD lustgarten:2024-andrew-lowy-clinical-accelerator-initiative-grant-an
  6. Targeting the MICAL2 signaling axis in pancreatic cancer R21CA273973↗
  7. Innovation & Collaboration grant: Andrew Lowy AWARD lustgarten:2022-andrew-lowy-innovation-collaboration-grant-andrew-lo
  8. RON Receptor in Pancreatic Cancer Biology and Therapy R01CA155620↗
  9. MICAL2 as a super-enhancer-associated target in pancreatic cancer AWARD pancan:2019-andrew-lowy-md-facs-mical2-as-a-super-enhancer-associated-ta
  10. Musashi-mediated control of pancreatic cancer growth and progression R01CA186043↗
  11. GPCRs: novel targets in cancer-associated fibroblasts R21CA189477↗

Closest collaborators

The 25 strongest of 340 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hervé Tiriac · 19 shared papers, 2020–2026 · strength 4.14
  2. Michael Karin · 5 shared papers, 1 shared grant, 2022–2026 · strength 1.81
  3. Jonathan Weitz · 8 shared papers, 2021–2026 · strength 1.67
  4. Robert F. Schwabe · 3 shared papers, 1 shared grant, 2022–2026 · strength 1.43
  5. Dannielle D. Engle · 7 shared papers, 2023–2026 · strength 1.33
  6. Peng Wu · 1 shared grant, 2026 · strength 1.26
  7. Elena Gabriela Chiorean · 10 shared papers, 2014–2026 · strength 1.09
  8. Paul A. Insel · 3 shared papers, 1 shared grant, 2015–2026 · strength 1.08
  9. Tannishtha Reya · 6 shared papers, 1 shared grant, 2016–2023 · strength 0.92
  10. Peter James McCormick · 3 shared papers, 2025–2026 · strength 0.87
  11. Cristina Salmerón · 3 shared papers, 2025–2026 · strength 0.87
  12. Cosimo Commisso · 5 shared papers, 2020–2025 · strength 0.86
  13. Philip A. Philip · 9 shared papers, 2013–2024 · strength 0.86
  14. Christian M. Metallo · 5 shared papers, 2022–2026 · strength 0.86
  15. Satoshi Ogawa · 4 shared papers, 2023–2026 · strength 0.84
  16. Tatiana Hurtado de Mendoza · 4 shared papers, 2021–2026 · strength 0.76
  17. Ronald M. Evans · 6 shared papers, 2017–2026 · strength 0.74
  18. Yijuan Zhang · 4 shared papers, 2020–2025 · strength 0.69
  19. Casie S. Kubota · 3 shared papers, 2026 · strength 0.68
  20. Andrea Wang‐Gillam · 6 shared papers, 2013–2024 · strength 0.67
  21. Beicheng Sun · 4 shared papers, 2022–2026 · strength 0.65
  22. Kazuki N. Sugahara · 3 shared papers, 2023–2026 · strength 0.61
  23. Kodai Suzuki · 3 shared papers, 2023–2026 · strength 0.61
  24. Norio Miyamura · 3 shared papers, 2023–2026 · strength 0.61
  25. Dana Backlund Cardin · 7 shared papers, 2016–2026 · strength 0.59

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.